Ying-Yang (YY-1) Expression and Fas in Biopsies of Children With Type IV Lupus Nephritis Correlates With the Clinical Condition

Rubén Márquez-Marín, a Berenice Sánchez Arellano, b César González-Bonilla, b Eunice Solís Vallejo, a José Luis Matamoros-Tapia, a and Sara Huerta-Yepez b

*a Servicio de Reumatología Pediátrica, Centro Médico Nacional Dr. Gaudencio González Garza La Raza, UMAE, México DF, México
b Unidad de Investigación Médica en Inmunología e Infectología, Hospital de Infectología, Centro Médico Nacional La Raza, IMSS, UMAE, México DF, México

Background: It has been demonstrated that Fas-mediated apoptosis participates in the physiopathology of lupus nephritis, although it is not clear whether it contributes to the development of the tissue damage. Since YY-1 down regulates Fas in cancer cell lines, it is reasonable to consider that this transcription factor may control Fas expression in lupus nephritis. The objective was to determine the correlation between YY-1 and Fas expression in renal biopsies from children with type IV lupus nephritis, and their association with the clinical condition of the patients.

Material and methods: Eighteen biopsies from children with type IV lupus nephritis and 5 controls were studied. Fas and YY-1 expression were determined by immunochemistry and quantified by densitometry analysis. The clinical conditions at the moment the biopsy were obtained from the clinical records and the results were analyzed through a one-way ANOVA with P < 0.005.

Results: The results of the densitometry analysis showed an inverse relationship between YY-1 and Fas expression. YY-1 was grouped according to the intensity of expression in low, moderate and high and compared with the expression of Fas. The lupus nephritis biopsies, which revealed high expression of YY-1, corresponded to patients with less number of clinical complications, better outcome, and fewer alterations on renal function. In contrast, low expression of YY-1 correlated with high Fas expression and worst clinical conditions.

Conclusions: The present study suggests that YY-1 regulates Fas expression in lupus nephritis and that it is associated with the clinical outcome of the patients, although further studies are necessary to determine whether it factor may serve as a prognosis factor. This is the first evidence of YY-1 participation in the physiopathology of lupus nephritis.

Key words: Lupus nephritis. Transcription factor YY-1. Fas. Apoptosis.

La expresión de Yin-Yang-1 (YY-1) y Fas en las biopsias de niños con nefritis lúpica tipo IV se correlaciona con la condición clínica

Antecedentes: La apoptosis mediada por Fas participa en la fisiopatología de la nefritis lúpica. Debido a que YY-1 regula negativamente el Fas en líneas celulares de cáncer, es razonable considerar que este factor de transcripción pueda controlar la expresión de Fas en la nefritis lúpica. El objetivo es determinar la correlación de la expresión de YY-1 y Fas en biopsias de niños con nefritis lúpica de tipo IV y su asociación con la condición clínica de los pacientes.

Material y métodos: Se estudiaron 18 biopsias de niños con nefritis lúpica de tipo IV y 5 controles. La expresión de Fas y YY-1 se determinó mediante inmunohistoquímica y se cuantificó mediante análisis densitométrico. Se obtuvo información sobre el estado clínico de los pacientes en el momento de la biopsia a partir de los expedientes, y los resultados se analizaron mediante ANOVA de una vía. Se consideró significativo un valor p < 0.005.

Resultados: Los resultados del análisis densitométrico muestran una relación inversa entre la expresión de YY-1 y Fas. Se agrupó YY-1, de acuerdo con la intensidad de su expresión, en baja, moderada y alta para poder compararla con la expresión de Fas. Las biopsias de nefritis lúpica que mostraron alta expresión de YY-1 correspondieron a pacientes con menor número de complicaciones clínicas, mejor desenlace y menor número de alteraciones en la función renal. En
of patients with type IV lupus nephritis and other glomerulonephritis, it was found that patients with lupus nephritis had a lower percentage of apoptosis, which had a negative correlation with creatinine clearance. The authors concluded that apoptosis is reduced in said illness and that this mechanism leads to chronic renal damage. In a study by Kirim et al, the relationship between the clinical course and apoptosis in renal biopsies of lupus nephritis was investigated; a correlation between the nuclear cells of the renal biopsy and the activity index of lupus nephritis was found. The authors concluded that apoptosis can be a prognostic indicator in this nephropathy.

Diverse studies demonstrate the importance that Fas has in the pathogeny of lupus nephritis. However, it is unknown which factors regulate its expression during the development of this illness. YY-1 is a transcription factor that participates in the positive and negative regulation of diverse genes in mammals. It has been demonstrated that YY-1 represses the transcription of the Fas gene by binding to a silencer region on its promoter. Overexpression of Fas induces a sensitization of tumor-cell lines to apoptosis mediated by this receptor. The participation of YY-1 has not been communicated until now in the pathogeny of lupus nephritis, so in this study we evaluated whether YY-1 could be related to the expression of Fas and, therefore, had any participation in the pathogeny of lupus nephritis.

Material and Method

Samples

Eighteen biopsies from pediatric male and female patients, aged 6 to 15 years of age, with type IV lupus nephritis confirmed by a pathologist from the same hospital who was an expert in kidney tissue, protocolized by the department of pediatric rheumatology and filed in the department of pathology of the Hospital CMN La Raza, IMSS. Five kidney biopsies from pediatric patients without any lesions were also included. The protocol was approved by the research committee of the Hospital General del CMN La Raza (project no. R-2006–3502-6, I.P. Dra Sara Huerta Yepez).

Immunohistochemistry

Fas and YY-1 determination was done through histochemistry. With the intention of reducing the variations between experiments, the reaction for each marker was done at the same time in all groups. Cuts were mounted on slides covered with silane. They were maintained in a bacteriologic oven at 62°C for 45 min, to deparaffinate, with the following process.
The samples were hydrated: 3 baths immersions in xylene, lasting 8 minutes, 2 immersions in 100% ethanol, 1 immersion in 90% ethanol, 1 immersion in 70% ethanol, and 1 in distilled water, each one for 5 minutes.

Antigen recovery was carried out with sodium citrate, boiling for 20 min and with subsequent immersions to eliminate the sodium citrate. Endogenous peroxidase activity was eliminated with methanol and 3% hydrogen peroxide, twice for 15 minutes. Non immune binding of antibodies to tissue was eliminated by submersion for 60 min in 2% normal pig serum. Afterwards, sections were incubated over-night at room temperature in humid chambers with anti-YY-1 (Santa Cruz, CA, United States) 1:250 and anti-Fas antibodies (Santa Cruz, CA, United States) 1:1.000. They were later incubated with the second Biotin link (DAKO) antibody, with streptavidine conjugated with radish peroxidase (HPR); finally, color was generated through the addition of DAB (dynamobenzidine) substrate for 3 min and 30 s; the reaction was stopped with tap water and counterstained with hematoxyllin 15 s. After that, the tissue was dehydrated with the following scheme: distilled water, 70% ethanol, 90% ethanol, 100% ethanol, and xylene in 5 minute-immersions each. Finally, preparations were covered with resin and let dry at room temperature.

Densitometry Analysis

Slides were analyzed on a microscope (Olimpus, BX-40), and the intensity of the immunostaining (Brown color) was quantified in 4 randomly chose fields, using an image analyzer with the Imagen-Pro® Plus software (Media Cybernetics,® Silver Spring, MD, United States).

<table>
<thead>
<tr>
<th>Number</th>
<th>Hystopathological Classification</th>
<th>Age</th>
<th>Gender</th>
<th>Time Since Onset of Symptoms, Months</th>
<th>CRI</th>
<th>Clinical Course</th>
<th>RF</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IV C</td>
<td>13</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Hypertensive crises</td>
<td>IRC</td>
</tr>
<tr>
<td>2</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>1</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>IV C</td>
<td>15</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>IV B</td>
<td>14</td>
<td>F</td>
<td>2</td>
<td>Yes</td>
<td>Uremic syndrome/varicella</td>
<td>Normal</td>
</tr>
<tr>
<td>6</td>
<td>IV C</td>
<td>15</td>
<td>M</td>
<td>3</td>
<td></td>
<td>Hypovolemic shock/ hematologic SLE</td>
<td>Normal</td>
</tr>
<tr>
<td>7</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>2</td>
<td>Yes</td>
<td>Uremic syndrome, peritonitis, metabolic alterations, hemodyalisis</td>
<td>Normal</td>
</tr>
<tr>
<td>8</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>3</td>
<td></td>
<td>Vascular purpura</td>
<td>Normal</td>
</tr>
<tr>
<td>9</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>1</td>
<td></td>
<td>UTI due to Staphilococcus coagulase negative</td>
<td>Normal</td>
</tr>
<tr>
<td>10</td>
<td>IV B</td>
<td>14</td>
<td>M</td>
<td>2</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>IV C</td>
<td>10</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>IV C</td>
<td>14</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>IV C</td>
<td>12</td>
<td>F</td>
<td>2</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>IV C</td>
<td>13</td>
<td>F</td>
<td>1</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>IV C</td>
<td>12</td>
<td>F</td>
<td>2</td>
<td></td>
<td>Severe pericardial effusion</td>
<td>Normal</td>
</tr>
<tr>
<td>16</td>
<td>IV C</td>
<td>6</td>
<td>F</td>
<td>4</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>IV C</td>
<td>12</td>
<td>M</td>
<td>3</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>IV C</td>
<td>12</td>
<td>F</td>
<td>&gt;6</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
</tbody>
</table>

*RF indicates renal function after 5 years (normal, creatinine <1 and normal uranalysis, and urinary sediment); CRI, chronic renal insufficiency; UTI, urinary tract infection; SLE, systemic lupus erythematosus; F, female; M, male.
Statistical Analysis

A database was elaborated and the information processed using the statistical software package Prisma® (GraphPad Software, Inc., San Diego, CA, USA). Data was presented as arithmetical means for each group and standard deviations. The evaluation of differences in the number of positive cells and the density of the expression of immunohistochemical reactions was done using one-way ANOVA. A Tukey multiple comparison analysis to identify differences between groups was done, with a level of significance of \( P = 0.05 \).

Results

Clinical Analysis

Files of children with a diagnosis of SLE according to the classification criteria proposed by the American College of Rheumatology and renal affection, for which a biopsy had been carried out, were reviewed. We included 18 biopsies with type IV lupus nephritis, according to the morphological classification proposed by WHO. Regarding distribution by gender, 15 (84%) were female and 3 (16%) male. Mean age was 12.8 (interval, 6-15) years. Clinical characteristics are shown in Tables 1 and 2. For evaluation purposes, our study population was divided into 2 groups, according to YY-1 expression. Group 1 included low to medium YY-1 expression and group 2, high expression. In group 1, which included 11 patients, 72.7% had microscopic hematuria, 63.6% had proteinuria (1-2 g/24 h), 45.4% had nephrotic syndrome and 91% had a creatinine clearance <50 mL/min/1.73 m\(^2\) BSA; at the same time, 63.6% of patients had low complement levels and hyperazoemia. Two patients in this group presented with uremic syndrome that required dialysis and in a third patient, chronic renal failure ensued.

Of the group with high YY-1 (7 patients), 100% presented microhematuria, 63.6% had proteinuria (1-2 g/24 h), 45.4% had nephrotic syndrome and 91% had creatinine clearance <50 mL/min/1.73 m\(^2\) BSA; at the same time, 63.6% of patients had low complement levels and hyperazoemia. None manifested acute renal failure or nephrotic syndrome.

Immunohistochemical Findings

YY-1 was found (80%-90% of positive cells) mainly in the proximal and distal convoluted tubes, both in the cortex and medulla of the kidney (Figures 1-3). In the healthy controls, expression was found in the same sites (Figure 1). YY-1 was mainly expressed in the distal tubular epithelium, with variable degrees of intensity with relation to the cellular proliferation, with a low expression (1%-30%), medium (31%-70%), and high (71%-100%, Figures 2E and 2F). The expression of this protein in the glomeruli was <30% with respect to the expression of Fas. Regarding Fas immunostaining, it was found mainly in the proximal and distal convoluted tubes both in the cortex as in the medulla of the kidney (90% of positive cells) (Figures 1-3).

Healthy renal controls had expression in the same sites (Figure 1), though clearly less that in patients with nephritis. Staining of the apical membrane and cytoplasm of the cells of the proximal convoluted tubes was seen (Figures 1D, 3C, and 3D). In some lesions, the basal membrane of the distal convoluted tubes presented a higher intensity of expression. In the glomerulus, lesions with more cell proliferation stained positively for Fas, its distribution was larger in the mesangial cells and in Bowmans’ capsule parietal cells, as in the mesangial matrix (Figures 1B, 3E, 3F).

Densitometry Analysis of Immunohistochemical Findings

Densitometry analysis of staining for Fas and YY-1 allowed for the elaboration of density expression graphs, processed
using the Prisma® statistical analysis software. In Figure 4 the density of expression of YY-1 and Fas was shown in the renal tubules of samples with lupus nephritis and controls. Densitometry showed an inversely proportional relationship between the expression of YY-1 and Fas ($P < .037$). YY-1 and Fas expression in the glomeruli do not reveal significant differences (data not shown).

In Figure 5 the density of expression of YY-1 and Fas is shown and a comparison of the expression of these 2 proteins in all analyzed cases, grouping YY-1 according to the intensity of expression is low (less than 30% of positive cells), medium (31%-70%) and high (71%-100%), observing an inverse relation that reveals high YY-1 and low Fas (last columns) ($P < .0003$).
Figure 2. Immunostaining of tissue with type IV lupus nephritis with a low expression of Fas and a high expression of YY-1. 

A: negative control (×40). B: ×100. C: moderate expression of Fas in the proximal and distal convoluted tubes (×40). D: a moderate expression of Fas in the cytoplasm and cell membrane of the proximal convoluted tubes (×100). E: intense expression of YY-1 in proximal and distal convoluted tubes, negative in the glomeruli (×40). F: intense expression of YY-1 in the cytoplasm of distal convoluted tubes; some positive nuclei can be observed (arrows), indicating activity of transcription factors; negative glomeruli (×100).
Figure 3. Immunostaining of type IV lupus nephritis tissue with a high expression of Fas and a low expression of YY-1. A: negative control (×40). B: ×100. C: intense expression of Fas in the proximal and distal convoluted tubes, negative in the glomeruli (×40). D: same patient, intense expression of Fas in the cytoplasm and membrane of the proximal convoluted tubes (×100). E: low expression of YY-1 in distal tubules (×40). F: at larger magnification (×100) a low expression, mainly in the cytoplasm of the distal convoluted tubules is shown; negative glomeruli can be seen.
It is known that apoptosis takes place by diverse physiopathologic mechanisms in autoimmune diseases and that Fas participates in the production of damage to glomeruli in SLE, because of its intense expression in the lupus nephropathy. On the other hand, it has been described that YY-1 regulates the transcription of diverse genes by means of 3 different routes, repressing, activating, and initiating transcription. There are studies that show the participation of YY-1 in the regulation of genes in tumor-like cell lines treated with nitric oxide, some genes of HIV, and certain alleles of chromosomes related to SLE. Recent studies show that YY-1 regulates the loss of the expression of Fas in a model of ovarian and prostate cancer. Nevertheless, no publications exist on the participation of YY-1 in the physiopathology of lupus nephritis and if this transcription factor regulates the loss of expression of Fas, a central protein in glomerular damage. The population studied with childhood lupus (18 patients) agrees with published data, type IV nephritis, predominance in women, an average age of 13 years and not affecting children of less than 5 years. The diagnosis of SLE was corroborated by the presence of antinuclear antibodies and double-stranded anti-DNA in all patients. Fifty-five percent presented, in addition, complement consumption. The group of low to moderate expression YY-1 displayed an unfavorable clinical course, with a greater percentage of macroscopic hematuria (27.7% of the patients), nephrotic syndrome (45%), lower creatinine clearance (91%), greater consumption of complement, and hyperazoemia (63.6%). Of these, 2 patients presented uremic syndrome that required dialysis and a third patient ended as chronic renal insufficiency. In contrast, the group of high YY-1 displayed a minor frequency of these alterations (no macroscopic hematuria or nephrotic syndrome, average creatinine clearance in 57%, and had hyperazoemia in 14%), and no one of this group had acute renal insufficiency. Although it is known that Fas is expressed mainly in the convoluted tubules, we found as much expression of Fas and YY-1 in tubules as in the glomeruli, mainly in lesions with a greater degree of cell proliferation, with a smaller density of expression for YY-1 and greater density of expression for Fas in these sites. Attention must be directed to the cellular distribution of YY-1 and Fas in the tubular level and mainly in the distal convoluted tubules apical membrane, important data for renal injury, because we know that there is great activity of ATPase dependent pumps on which some hormonal factors like aldosterone and vasopressin act, as well as regulation of Na and K, which are altered in the inflammatory process. The mitochondrial activity of this region indicates a greater amount of caspases. In the proximal convoluted tubules, where staining was also seen in variable degrees of intensity, there was a greater percentage of positive Fas cells in the lesions with greater cellular proliferation. It is in this site where greater reabsorption of the glomerular filtrate corresponds to solutos, and this damage goes hand in hand with a lower creatinine clearance, acute renal damage and hyperazoemia. The densitometry analysis sample shows YY-1 expression is inverse to the expression of Fas. Is interesting that, when YY-1 was found with an elevated density, the...
expression of Fas was lower, which correlated with less clinical complications, a more favorable course of the disease, as well as less alterations in the renal function. It is interesting to point out that the high expression of YY-1 was similar in patients who had a favorable clinical course and in healthy controls. This fact indicates that YY-1 is important in the control of kidney homeostasis, something which had not been published to date. These findings indicate that YY-1 regulates the loss of Fas expression in this type of injuries and agrees with reports in which this regulation takes place in some neoplastic cells. The results indicate that YY-1 participates in the physiopathology of lupus nephritis, a fact that had not been explored previously. This work requires more extensive study of YY-1 to evaluate its utility as a prognostic factor in this disease.

References